Demographic and baseline characteristics according to antithrombotic therapy at baseline discharge
| . | No antithrombotic (N = 586) . | Only antiplatelet drugs (N = 681) . | Only VKA (N = 4066) . | Only NOACs (N = 3167) . | Antiplatelet drugs + OAC (N = 1163) . | P-value . |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age (years), median (IQR) | 61 (51–73) | 72 (62–78) | 71 (64–78) | 70 (62–77) | 72 (65–78) | <0.0001 |
| Female, n (%) | 223 (38.1) | 289 (42.4) | 1729 (42.5) | 1272 (40.2) | 374 (32.2) | <0.0001 |
| Type of AF, n (%) | <0.0001 | |||||
| First diagnosed | 136 (23.9) | 127 (19.2) | 386 (9.6) | 626 (20.0) | 189 (16.7) | |
| Paroxysmal | 231 (40.7) | 285 (43.1) | 821 (20.5) | 844 (27.0) | 288 (25.4) | |
| Persistent | 78 (13.7) | 80 (12.1) | 711 (17.7) | 814 (26.0) | 215 (19.0) | |
| LS persistent | 9 (1.6) | 18 (2.7) | 206 (5.1) | 158 (5.1) | 35 (3.1) | |
| Permanent | 114 (20.1) | 151 (22.8) | 1884 (47.0) | 683 (21.9) | 405 (35.8) | |
| Concomitant diseases, n (%) | ||||||
| Hypertension | 188 (32.5) | 412 (61.1) | 2631 (65.2) | 1897 (60.4) | 791 (68.5) | <0.0001 |
| CAD | 91 (16.2) | 334 (52.8) | 850 (22.3) | 498 (16.4) | 834 (76.3) | <0.0001 |
| Previous MI | 40 (44.0) | 160 (47.9) | 325 (38.2) | 194 (39.0) | 432 (51.8) | <0.0001 |
| Heart failure | 135 (23.4) | 323 (47.9) | 1735 (42.9) | 934 (29.8) | 590 (51.1) | <0.0001 |
| Valvular disease | 157 (27.4) | 305 (46.0) | 2362 (59.1) | 1316 (42.5) | 625 (54.6) | <0.0001 |
| Dilated cardiomyopathy | 24 (4.2) | 54 (8.0) | 419 (10.4) | 185 (5.9) | 142 (12.4) | <0.0001 |
| Hypertrophic cardiomyopathy | 9 (1.6) | 16 (2.4) | 154 (3.8) | 76 (2.4) | 41 (3.6) | 0.0007 |
| Restrictive cardiomyopathy | 2 (0.3) | 1 (0.1) | 11 (0.3) | 4 (0.1) | 2 (0.2) | 0.5788 |
| Other cardiomyopathy | 12 (2.1) | 24 (3.6) | 161 (4.0) | 97 (3.1) | 56 (4.8) | 0.0102 |
| Congenital heart disease | 6 (1.0) | 9 (1.3) | 50 (1.2) | 25 (0.8) | 12 (1.0) | 0.3852 |
| PAH | 21 (3.7) | 53 (8.0) | 345 (8.6) | 128 (4.1) | 93 (8.1) | <0.0001 |
| Cardiovascular risk factors, n (%) | ||||||
| Diabetes mellitus | 86 (14.8) | 161 (23.7) | 943 (23.3) | 595 (18.9) | 409 (35.5) | <0.0001 |
| Lipid disorder | 148 (26.6) | 295 (45.7) | 1651 (42.5) | 1138 (37.5) | 617 (55.1) | <0.0001 |
| Current smoker | 85 (15.5) | 71 (11.2) | 305 (8.2) | 244 (8.2) | 124 (11.3) | <0.0001 |
| No regular exercise | 170 (33.4) | 290 (47.6) | 1483 (42.5) | 989 (37.0) | 525 (50.9) | <0.0001 |
| Other comorbidities, n (%) | ||||||
| Previous stroke | 14 (2.4) | 40 (6.0) | 262 (6.5) | 189 (6.0) | 83 (7.2) | 0.0005 |
| Previous TIA | 6 (1.0) | 18 (2.7) | 126 (3.1) | 119 (3.8) | 41 (3.6) | 0.0048 |
| Previous bleedings | 39 (6.8) | 59 (8.8) | 166 (4.1) | 163 (5.2) | 68 (5.9) | <0.0001 |
| PAD | 26 (4.5) | 84 (12.8) | 299 (7.5) | 176 (5.7) | 175 (15.5) | <0.0001 |
| Chronic kidney disease | 37 (6.3) | 123 (18.2) | 504 (12.5) | 304 (9.6) | 223 (19.3) | <0.0001 |
| COPD | 34 (5.9) | 60 (8.9) | 388 (9.6) | 226 (7.2) | 147 (12.7) | <0.0001 |
| Malignancy | 47 (8.0) | 54 (8.0) | 285 (7.0) | 262 (8.3) | 89 (7.7) | 0.3309 |
| Thyroid disease/disorder | 57 (9.9) | 75 (11.4) | 615 (15.4) | 452 (14.5) | 166 (14.5) | 0.0017 |
| Main reason for admission/consultation, n (%) | <0.0001 | |||||
| AF | 447 (76.3) | 368 (54.0) | 2565 (63.1) | 2557 (80.7) | 537 (46.2) | |
| ACS | 13 (2.2) | 84 (12.3) | 36 (0.9) | 19 (0.6) | 161 (13.8) | |
| Valvular disease | 9 (1.5) | 19 (2.8) | 177 (4.4) | 17 (0.5) | 52 (4.5) | |
| Hypertension | 21 (3.6) | 10 (1.5) | 94 (2.3) | 51 (1.6) | 19 (1.6) | |
| Heart failure | 22 (3.8) | 67 (9.8) | 502 (12.3) | 207 (6.5) | 142 (12.2) | |
| Other CAD | 8 (1.4) | 41 (6.0) | 80 (2.0) | 36 (1.1) | 96 (8.3) | |
| Other CV | 28 (4.8) | 65 (9.5) | 363 (8.9) | 159 (5.0) | 105 (9.0) | |
| Other non-CV | 38 (6.5) | 27 (4.0) | 248 (6.1) | 121 (3.8) | 51 (4.4) | |
| Symptomatic status, n (%) | <0.0001 | |||||
| EHRA I | 261 (44.5) | 337 (49.5) | 1942 (47.8) | 1328 (41.9) | 519 (44.6) | |
| EHRA II–III–IV | 325 (55.5) | 344 (50.5) | 2124 (52.2) | 1839 (58.1) | 644 (55.4) | |
| . | No antithrombotic (N = 586) . | Only antiplatelet drugs (N = 681) . | Only VKA (N = 4066) . | Only NOACs (N = 3167) . | Antiplatelet drugs + OAC (N = 1163) . | P-value . |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age (years), median (IQR) | 61 (51–73) | 72 (62–78) | 71 (64–78) | 70 (62–77) | 72 (65–78) | <0.0001 |
| Female, n (%) | 223 (38.1) | 289 (42.4) | 1729 (42.5) | 1272 (40.2) | 374 (32.2) | <0.0001 |
| Type of AF, n (%) | <0.0001 | |||||
| First diagnosed | 136 (23.9) | 127 (19.2) | 386 (9.6) | 626 (20.0) | 189 (16.7) | |
| Paroxysmal | 231 (40.7) | 285 (43.1) | 821 (20.5) | 844 (27.0) | 288 (25.4) | |
| Persistent | 78 (13.7) | 80 (12.1) | 711 (17.7) | 814 (26.0) | 215 (19.0) | |
| LS persistent | 9 (1.6) | 18 (2.7) | 206 (5.1) | 158 (5.1) | 35 (3.1) | |
| Permanent | 114 (20.1) | 151 (22.8) | 1884 (47.0) | 683 (21.9) | 405 (35.8) | |
| Concomitant diseases, n (%) | ||||||
| Hypertension | 188 (32.5) | 412 (61.1) | 2631 (65.2) | 1897 (60.4) | 791 (68.5) | <0.0001 |
| CAD | 91 (16.2) | 334 (52.8) | 850 (22.3) | 498 (16.4) | 834 (76.3) | <0.0001 |
| Previous MI | 40 (44.0) | 160 (47.9) | 325 (38.2) | 194 (39.0) | 432 (51.8) | <0.0001 |
| Heart failure | 135 (23.4) | 323 (47.9) | 1735 (42.9) | 934 (29.8) | 590 (51.1) | <0.0001 |
| Valvular disease | 157 (27.4) | 305 (46.0) | 2362 (59.1) | 1316 (42.5) | 625 (54.6) | <0.0001 |
| Dilated cardiomyopathy | 24 (4.2) | 54 (8.0) | 419 (10.4) | 185 (5.9) | 142 (12.4) | <0.0001 |
| Hypertrophic cardiomyopathy | 9 (1.6) | 16 (2.4) | 154 (3.8) | 76 (2.4) | 41 (3.6) | 0.0007 |
| Restrictive cardiomyopathy | 2 (0.3) | 1 (0.1) | 11 (0.3) | 4 (0.1) | 2 (0.2) | 0.5788 |
| Other cardiomyopathy | 12 (2.1) | 24 (3.6) | 161 (4.0) | 97 (3.1) | 56 (4.8) | 0.0102 |
| Congenital heart disease | 6 (1.0) | 9 (1.3) | 50 (1.2) | 25 (0.8) | 12 (1.0) | 0.3852 |
| PAH | 21 (3.7) | 53 (8.0) | 345 (8.6) | 128 (4.1) | 93 (8.1) | <0.0001 |
| Cardiovascular risk factors, n (%) | ||||||
| Diabetes mellitus | 86 (14.8) | 161 (23.7) | 943 (23.3) | 595 (18.9) | 409 (35.5) | <0.0001 |
| Lipid disorder | 148 (26.6) | 295 (45.7) | 1651 (42.5) | 1138 (37.5) | 617 (55.1) | <0.0001 |
| Current smoker | 85 (15.5) | 71 (11.2) | 305 (8.2) | 244 (8.2) | 124 (11.3) | <0.0001 |
| No regular exercise | 170 (33.4) | 290 (47.6) | 1483 (42.5) | 989 (37.0) | 525 (50.9) | <0.0001 |
| Other comorbidities, n (%) | ||||||
| Previous stroke | 14 (2.4) | 40 (6.0) | 262 (6.5) | 189 (6.0) | 83 (7.2) | 0.0005 |
| Previous TIA | 6 (1.0) | 18 (2.7) | 126 (3.1) | 119 (3.8) | 41 (3.6) | 0.0048 |
| Previous bleedings | 39 (6.8) | 59 (8.8) | 166 (4.1) | 163 (5.2) | 68 (5.9) | <0.0001 |
| PAD | 26 (4.5) | 84 (12.8) | 299 (7.5) | 176 (5.7) | 175 (15.5) | <0.0001 |
| Chronic kidney disease | 37 (6.3) | 123 (18.2) | 504 (12.5) | 304 (9.6) | 223 (19.3) | <0.0001 |
| COPD | 34 (5.9) | 60 (8.9) | 388 (9.6) | 226 (7.2) | 147 (12.7) | <0.0001 |
| Malignancy | 47 (8.0) | 54 (8.0) | 285 (7.0) | 262 (8.3) | 89 (7.7) | 0.3309 |
| Thyroid disease/disorder | 57 (9.9) | 75 (11.4) | 615 (15.4) | 452 (14.5) | 166 (14.5) | 0.0017 |
| Main reason for admission/consultation, n (%) | <0.0001 | |||||
| AF | 447 (76.3) | 368 (54.0) | 2565 (63.1) | 2557 (80.7) | 537 (46.2) | |
| ACS | 13 (2.2) | 84 (12.3) | 36 (0.9) | 19 (0.6) | 161 (13.8) | |
| Valvular disease | 9 (1.5) | 19 (2.8) | 177 (4.4) | 17 (0.5) | 52 (4.5) | |
| Hypertension | 21 (3.6) | 10 (1.5) | 94 (2.3) | 51 (1.6) | 19 (1.6) | |
| Heart failure | 22 (3.8) | 67 (9.8) | 502 (12.3) | 207 (6.5) | 142 (12.2) | |
| Other CAD | 8 (1.4) | 41 (6.0) | 80 (2.0) | 36 (1.1) | 96 (8.3) | |
| Other CV | 28 (4.8) | 65 (9.5) | 363 (8.9) | 159 (5.0) | 105 (9.0) | |
| Other non-CV | 38 (6.5) | 27 (4.0) | 248 (6.1) | 121 (3.8) | 51 (4.4) | |
| Symptomatic status, n (%) | <0.0001 | |||||
| EHRA I | 261 (44.5) | 337 (49.5) | 1942 (47.8) | 1328 (41.9) | 519 (44.6) | |
| EHRA II–III–IV | 325 (55.5) | 344 (50.5) | 2124 (52.2) | 1839 (58.1) | 644 (55.4) | |
ACS, acute coronary syndrome; AF, atrial fibrillation; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; EHRA, European Heart Rhythm Association; IQR, interquartile range; MI, myocardial infarction; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulants; PAD, peripheral artery disease; PAH, pulmonary artery hypertension; TIA, transient ischaemic attack; VKA, vitamin K antagonist.
Demographic and baseline characteristics according to antithrombotic therapy at baseline discharge
| . | No antithrombotic (N = 586) . | Only antiplatelet drugs (N = 681) . | Only VKA (N = 4066) . | Only NOACs (N = 3167) . | Antiplatelet drugs + OAC (N = 1163) . | P-value . |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age (years), median (IQR) | 61 (51–73) | 72 (62–78) | 71 (64–78) | 70 (62–77) | 72 (65–78) | <0.0001 |
| Female, n (%) | 223 (38.1) | 289 (42.4) | 1729 (42.5) | 1272 (40.2) | 374 (32.2) | <0.0001 |
| Type of AF, n (%) | <0.0001 | |||||
| First diagnosed | 136 (23.9) | 127 (19.2) | 386 (9.6) | 626 (20.0) | 189 (16.7) | |
| Paroxysmal | 231 (40.7) | 285 (43.1) | 821 (20.5) | 844 (27.0) | 288 (25.4) | |
| Persistent | 78 (13.7) | 80 (12.1) | 711 (17.7) | 814 (26.0) | 215 (19.0) | |
| LS persistent | 9 (1.6) | 18 (2.7) | 206 (5.1) | 158 (5.1) | 35 (3.1) | |
| Permanent | 114 (20.1) | 151 (22.8) | 1884 (47.0) | 683 (21.9) | 405 (35.8) | |
| Concomitant diseases, n (%) | ||||||
| Hypertension | 188 (32.5) | 412 (61.1) | 2631 (65.2) | 1897 (60.4) | 791 (68.5) | <0.0001 |
| CAD | 91 (16.2) | 334 (52.8) | 850 (22.3) | 498 (16.4) | 834 (76.3) | <0.0001 |
| Previous MI | 40 (44.0) | 160 (47.9) | 325 (38.2) | 194 (39.0) | 432 (51.8) | <0.0001 |
| Heart failure | 135 (23.4) | 323 (47.9) | 1735 (42.9) | 934 (29.8) | 590 (51.1) | <0.0001 |
| Valvular disease | 157 (27.4) | 305 (46.0) | 2362 (59.1) | 1316 (42.5) | 625 (54.6) | <0.0001 |
| Dilated cardiomyopathy | 24 (4.2) | 54 (8.0) | 419 (10.4) | 185 (5.9) | 142 (12.4) | <0.0001 |
| Hypertrophic cardiomyopathy | 9 (1.6) | 16 (2.4) | 154 (3.8) | 76 (2.4) | 41 (3.6) | 0.0007 |
| Restrictive cardiomyopathy | 2 (0.3) | 1 (0.1) | 11 (0.3) | 4 (0.1) | 2 (0.2) | 0.5788 |
| Other cardiomyopathy | 12 (2.1) | 24 (3.6) | 161 (4.0) | 97 (3.1) | 56 (4.8) | 0.0102 |
| Congenital heart disease | 6 (1.0) | 9 (1.3) | 50 (1.2) | 25 (0.8) | 12 (1.0) | 0.3852 |
| PAH | 21 (3.7) | 53 (8.0) | 345 (8.6) | 128 (4.1) | 93 (8.1) | <0.0001 |
| Cardiovascular risk factors, n (%) | ||||||
| Diabetes mellitus | 86 (14.8) | 161 (23.7) | 943 (23.3) | 595 (18.9) | 409 (35.5) | <0.0001 |
| Lipid disorder | 148 (26.6) | 295 (45.7) | 1651 (42.5) | 1138 (37.5) | 617 (55.1) | <0.0001 |
| Current smoker | 85 (15.5) | 71 (11.2) | 305 (8.2) | 244 (8.2) | 124 (11.3) | <0.0001 |
| No regular exercise | 170 (33.4) | 290 (47.6) | 1483 (42.5) | 989 (37.0) | 525 (50.9) | <0.0001 |
| Other comorbidities, n (%) | ||||||
| Previous stroke | 14 (2.4) | 40 (6.0) | 262 (6.5) | 189 (6.0) | 83 (7.2) | 0.0005 |
| Previous TIA | 6 (1.0) | 18 (2.7) | 126 (3.1) | 119 (3.8) | 41 (3.6) | 0.0048 |
| Previous bleedings | 39 (6.8) | 59 (8.8) | 166 (4.1) | 163 (5.2) | 68 (5.9) | <0.0001 |
| PAD | 26 (4.5) | 84 (12.8) | 299 (7.5) | 176 (5.7) | 175 (15.5) | <0.0001 |
| Chronic kidney disease | 37 (6.3) | 123 (18.2) | 504 (12.5) | 304 (9.6) | 223 (19.3) | <0.0001 |
| COPD | 34 (5.9) | 60 (8.9) | 388 (9.6) | 226 (7.2) | 147 (12.7) | <0.0001 |
| Malignancy | 47 (8.0) | 54 (8.0) | 285 (7.0) | 262 (8.3) | 89 (7.7) | 0.3309 |
| Thyroid disease/disorder | 57 (9.9) | 75 (11.4) | 615 (15.4) | 452 (14.5) | 166 (14.5) | 0.0017 |
| Main reason for admission/consultation, n (%) | <0.0001 | |||||
| AF | 447 (76.3) | 368 (54.0) | 2565 (63.1) | 2557 (80.7) | 537 (46.2) | |
| ACS | 13 (2.2) | 84 (12.3) | 36 (0.9) | 19 (0.6) | 161 (13.8) | |
| Valvular disease | 9 (1.5) | 19 (2.8) | 177 (4.4) | 17 (0.5) | 52 (4.5) | |
| Hypertension | 21 (3.6) | 10 (1.5) | 94 (2.3) | 51 (1.6) | 19 (1.6) | |
| Heart failure | 22 (3.8) | 67 (9.8) | 502 (12.3) | 207 (6.5) | 142 (12.2) | |
| Other CAD | 8 (1.4) | 41 (6.0) | 80 (2.0) | 36 (1.1) | 96 (8.3) | |
| Other CV | 28 (4.8) | 65 (9.5) | 363 (8.9) | 159 (5.0) | 105 (9.0) | |
| Other non-CV | 38 (6.5) | 27 (4.0) | 248 (6.1) | 121 (3.8) | 51 (4.4) | |
| Symptomatic status, n (%) | <0.0001 | |||||
| EHRA I | 261 (44.5) | 337 (49.5) | 1942 (47.8) | 1328 (41.9) | 519 (44.6) | |
| EHRA II–III–IV | 325 (55.5) | 344 (50.5) | 2124 (52.2) | 1839 (58.1) | 644 (55.4) | |
| . | No antithrombotic (N = 586) . | Only antiplatelet drugs (N = 681) . | Only VKA (N = 4066) . | Only NOACs (N = 3167) . | Antiplatelet drugs + OAC (N = 1163) . | P-value . |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age (years), median (IQR) | 61 (51–73) | 72 (62–78) | 71 (64–78) | 70 (62–77) | 72 (65–78) | <0.0001 |
| Female, n (%) | 223 (38.1) | 289 (42.4) | 1729 (42.5) | 1272 (40.2) | 374 (32.2) | <0.0001 |
| Type of AF, n (%) | <0.0001 | |||||
| First diagnosed | 136 (23.9) | 127 (19.2) | 386 (9.6) | 626 (20.0) | 189 (16.7) | |
| Paroxysmal | 231 (40.7) | 285 (43.1) | 821 (20.5) | 844 (27.0) | 288 (25.4) | |
| Persistent | 78 (13.7) | 80 (12.1) | 711 (17.7) | 814 (26.0) | 215 (19.0) | |
| LS persistent | 9 (1.6) | 18 (2.7) | 206 (5.1) | 158 (5.1) | 35 (3.1) | |
| Permanent | 114 (20.1) | 151 (22.8) | 1884 (47.0) | 683 (21.9) | 405 (35.8) | |
| Concomitant diseases, n (%) | ||||||
| Hypertension | 188 (32.5) | 412 (61.1) | 2631 (65.2) | 1897 (60.4) | 791 (68.5) | <0.0001 |
| CAD | 91 (16.2) | 334 (52.8) | 850 (22.3) | 498 (16.4) | 834 (76.3) | <0.0001 |
| Previous MI | 40 (44.0) | 160 (47.9) | 325 (38.2) | 194 (39.0) | 432 (51.8) | <0.0001 |
| Heart failure | 135 (23.4) | 323 (47.9) | 1735 (42.9) | 934 (29.8) | 590 (51.1) | <0.0001 |
| Valvular disease | 157 (27.4) | 305 (46.0) | 2362 (59.1) | 1316 (42.5) | 625 (54.6) | <0.0001 |
| Dilated cardiomyopathy | 24 (4.2) | 54 (8.0) | 419 (10.4) | 185 (5.9) | 142 (12.4) | <0.0001 |
| Hypertrophic cardiomyopathy | 9 (1.6) | 16 (2.4) | 154 (3.8) | 76 (2.4) | 41 (3.6) | 0.0007 |
| Restrictive cardiomyopathy | 2 (0.3) | 1 (0.1) | 11 (0.3) | 4 (0.1) | 2 (0.2) | 0.5788 |
| Other cardiomyopathy | 12 (2.1) | 24 (3.6) | 161 (4.0) | 97 (3.1) | 56 (4.8) | 0.0102 |
| Congenital heart disease | 6 (1.0) | 9 (1.3) | 50 (1.2) | 25 (0.8) | 12 (1.0) | 0.3852 |
| PAH | 21 (3.7) | 53 (8.0) | 345 (8.6) | 128 (4.1) | 93 (8.1) | <0.0001 |
| Cardiovascular risk factors, n (%) | ||||||
| Diabetes mellitus | 86 (14.8) | 161 (23.7) | 943 (23.3) | 595 (18.9) | 409 (35.5) | <0.0001 |
| Lipid disorder | 148 (26.6) | 295 (45.7) | 1651 (42.5) | 1138 (37.5) | 617 (55.1) | <0.0001 |
| Current smoker | 85 (15.5) | 71 (11.2) | 305 (8.2) | 244 (8.2) | 124 (11.3) | <0.0001 |
| No regular exercise | 170 (33.4) | 290 (47.6) | 1483 (42.5) | 989 (37.0) | 525 (50.9) | <0.0001 |
| Other comorbidities, n (%) | ||||||
| Previous stroke | 14 (2.4) | 40 (6.0) | 262 (6.5) | 189 (6.0) | 83 (7.2) | 0.0005 |
| Previous TIA | 6 (1.0) | 18 (2.7) | 126 (3.1) | 119 (3.8) | 41 (3.6) | 0.0048 |
| Previous bleedings | 39 (6.8) | 59 (8.8) | 166 (4.1) | 163 (5.2) | 68 (5.9) | <0.0001 |
| PAD | 26 (4.5) | 84 (12.8) | 299 (7.5) | 176 (5.7) | 175 (15.5) | <0.0001 |
| Chronic kidney disease | 37 (6.3) | 123 (18.2) | 504 (12.5) | 304 (9.6) | 223 (19.3) | <0.0001 |
| COPD | 34 (5.9) | 60 (8.9) | 388 (9.6) | 226 (7.2) | 147 (12.7) | <0.0001 |
| Malignancy | 47 (8.0) | 54 (8.0) | 285 (7.0) | 262 (8.3) | 89 (7.7) | 0.3309 |
| Thyroid disease/disorder | 57 (9.9) | 75 (11.4) | 615 (15.4) | 452 (14.5) | 166 (14.5) | 0.0017 |
| Main reason for admission/consultation, n (%) | <0.0001 | |||||
| AF | 447 (76.3) | 368 (54.0) | 2565 (63.1) | 2557 (80.7) | 537 (46.2) | |
| ACS | 13 (2.2) | 84 (12.3) | 36 (0.9) | 19 (0.6) | 161 (13.8) | |
| Valvular disease | 9 (1.5) | 19 (2.8) | 177 (4.4) | 17 (0.5) | 52 (4.5) | |
| Hypertension | 21 (3.6) | 10 (1.5) | 94 (2.3) | 51 (1.6) | 19 (1.6) | |
| Heart failure | 22 (3.8) | 67 (9.8) | 502 (12.3) | 207 (6.5) | 142 (12.2) | |
| Other CAD | 8 (1.4) | 41 (6.0) | 80 (2.0) | 36 (1.1) | 96 (8.3) | |
| Other CV | 28 (4.8) | 65 (9.5) | 363 (8.9) | 159 (5.0) | 105 (9.0) | |
| Other non-CV | 38 (6.5) | 27 (4.0) | 248 (6.1) | 121 (3.8) | 51 (4.4) | |
| Symptomatic status, n (%) | <0.0001 | |||||
| EHRA I | 261 (44.5) | 337 (49.5) | 1942 (47.8) | 1328 (41.9) | 519 (44.6) | |
| EHRA II–III–IV | 325 (55.5) | 344 (50.5) | 2124 (52.2) | 1839 (58.1) | 644 (55.4) | |
ACS, acute coronary syndrome; AF, atrial fibrillation; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; EHRA, European Heart Rhythm Association; IQR, interquartile range; MI, myocardial infarction; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulants; PAD, peripheral artery disease; PAH, pulmonary artery hypertension; TIA, transient ischaemic attack; VKA, vitamin K antagonist.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
